CTLA4 and arthritic joint disease: However, this inhibition was neutralized when the mice received a combination of anti-PD-1 and anti-CTLA-4 mAbs, exacerbating arthritis; this suggests that while ICIs effectively activate the immune system to battle tumors, they also significantly increase the risk of irAEs, such as arthritis [116, 117].